sales orders for the us

SX ANNOUNCEMENT

CARDIOCEL® SALES UPDATE – 1
st
SALES ORDERS FOR THE US
? Admedus gets first sales orders in the US market
? Launched in Europe with key centres targeted
? CardioCel® on show at AATS conference in Toronto this month

Brisbane, Australia, 7th May 2014
Admedus (ASX: AHZ) today announced further progress on the launch of CardioCel®,
including the first sales orders for the product in the US market. The initial US sales
orders are ahead of the expected mid-year timing the Company previously forecast.
The focus for our team now will be to get CardioCel® used in key centres across
Europe and the US.
“This is an important milestone for the Company as we look to grow our revenue over
the coming 12 months and beyond” said Admedus CEO Mr. Lee Rodne “we are aiming
for CardioCel® to be in use in 15 key centres in Europe and the US over the next 12
months, which will provide us with a significant presence in the market.”
US
Admedus has now received the first sales orders for CardioCel® in the US market. The
Company presented CardioCel® to US cardio-thoracic surgeons during the recent
American Association of Thoracic Surgeons (AATS) conference in Toronto. The sales
team have been working with US based cardio-thoracic surgeons, communicating the
benefits of CardioCel® and its advantages over existing products on the market.
Europe
In Europe, Admedus officially launched CardioCel® late in 2013, with the aim of
introducing it into 15 key cardio-thoracic centres. To date, CardioCel® has been used
in 8 of the target centres in Europe and the Company expects several more to come
on stream by mid-year, which is on par with our initial expectations. Surgeons who
have used CardioCel® in surgical procedures have not reported any issues.
Rest of the World
Admedus is currently seeking approval in a number of other jurisdictions to meet its
global launch plans. CardioCel® continues to be used in Australia under the Authorised
Prescriber Scheme with over 100 patients implanted.